ABBV Sep 2020 92.500 put

OPR - OPR Delayed Price. Currency in USD
15.53
0.00 (0.00%)
As of 3:48PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close15.53
Open15.53
Bid12.00
Ask12.50
Strike92.50
Expire Date2020-09-18
Day's Range15.53 - 15.53
Contract RangeN/A
Volume3
Open Interest39
  • GlobeNewswire

    Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

    Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.

  • PR Newswire

    AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.

  • PR Newswire

    New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combination with rituximab (VenR) in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). The updated data from the Phase 3 MURANO trial four-year analysis (median follow-up of 48 months with all patients off VENCLEXTA/VENCLYXTO treatment for a median of 22 months) showed that patients with R/R CLL who completed the chemotherapy-free, two-year fixed duration course of VENCLEXTA/VENCLYXTO treatment combination maintained progression-free survival (PFS) and overall survival (OS). Patients who completed treatment with the VENCLEXTA/VENCLYXTO combination also achieved higher rates of minimal residual disease (MRD)-negativity and complete remissions compared to those treated with a standard of care, bendamustine plus rituximab (BR).1 The full results were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (abstract 355).

  • PR Newswire

    More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA® (ibrutinib) monotherapy compared to later lines of therapy (LOT) extended progression-free survival (PFS) and increased the likelihood of a complete response (CR) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) – demonstrating that some patients achieved a disappearance of any signs of disease.

  • PR Newswire

    Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), which is part of the National Institutes of Health. Study results showed superior progression-free survival (PFS) and overall survival (OS) in patients with chronic lymphocytic leukemia (CLL) new to treatment.

  • PR Newswire

    IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial,1 evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Results showed that patients who received up to 12 cycles of the combination regimen achieved high rates of undetectable minimal residual disease (uMRD) in both peripheral blood (PB; 75 percent of patients) and in bone marrow (BM; 72 percent of patients). Safety data were consistent with the known safety profiles of IMBRUVICA and VENCLEXTA/VENCLYXTO used as individual therapies.

  • GlobeNewswire

    Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

    Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported safety and biomarker data from the single ascending dose (SAD) phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) meeting being held December 4-6 in San Diego, California.

  • Reuters

    Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

    UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease. UCB's drug, bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company. AbbVie's Humira is the world's top selling drug and treats rheumatoid arthritis and psoriasis.

  • AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    CNW Group

    AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

    AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

  • Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?
    Investor's Business Daily

    Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?

    Merck stock is on an upswing with a 14% gain in the first 11 full months of 2019. Meanwhile shares of other pharma companies grabbed a smaller gain. Is it time to give MRK stock a shot?

  • J&J Stock Witnesses Volatility in '19: What to Expect in 2020
    Zacks

    J&J Stock Witnesses Volatility in '19: What to Expect in 2020

    Here we discuss the ups and downs of J&J's (JNJ) stock this year.

  • AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

    AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Investopedia

    Where to Buy Booming Biotech ETFs

    Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

  • TheStreet.com

    [video]AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug

    AbbVie's fledgling rheumatoid arthritis treatment Rinvoq is showing promise and appears to be tracking "meaningfully ahead of expectations," according to analysts at Piper Jaffray. Analyst Christopher Raymond reiterated the firm's overweight rating on the North Chicago biopharma while increasing its price target to $92 from $90. At last check Tuesday AbbVie was trading down 1.2% at $86.

  • AbbVie (ABBV) Stock Moves -0.79%: What You Should Know
    Zacks

    AbbVie (ABBV) Stock Moves -0.79%: What You Should Know

    AbbVie (ABBV) closed the most recent trading day at $87.04, moving -0.79% from the previous trading session.

  • Barrons.com

    Disney Stock Is Loved by Wall Street. Its Bonds? Not So Much.

    Credit-research firm Gimme Credit is bearish on the debt of the media conglomerate as well as AbbVie’s bonds.

  • 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - December 02, 2019
    Zacks

    3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - December 02, 2019

    The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

  • AbbVie (ABBV) Up 10.3% Since Last Earnings Report: Can It Continue?
    Zacks

    AbbVie (ABBV) Up 10.3% Since Last Earnings Report: Can It Continue?

    AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Did Hedge Funds Drop The Ball On AbbVie Inc (ABBV) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On AbbVie Inc (ABBV) ?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Zacks

    Market Serves Up More Records for Thanksgiving

    Market Serves Up More Records for Thanksgiving

  • Financial Times

    Why some corporate bond investors see higher risk in higher ratings

    A topsy-turvy thesis is gaining traction among debt investors, with some fund managers arguing that the supposed safety of buying the highest-rated US corporate bonds is an illusion. Triple B debt is typically seen as a potential breaking point in a long-overdue reckoning in the corporate debt markets.

  • 3 Stocks for Value Investors to Buy as Market Reaches New High
    Zacks

    3 Stocks for Value Investors to Buy as Market Reaches New High

    The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.

  • Johnson Adviser Warns of Chance of Hung Parliament: U.K. Votes
    Bloomberg

    Johnson Adviser Warns of Chance of Hung Parliament: U.K. Votes

    (Bloomberg) -- Sign up to our Brexit Bulletin, follow us @Brexit and subscribe to our podcast.Jeremy Corbyn accused Boris Johnson’s Tories of risking the National Health Service in secret talks with the U.S. as he sought to shift the election campaign away from allegations of antisemitism. Johnson denied the U.K.’s free-to-use health care system is up for sale after the Labour leader unveiled previously redacted documents about negotiations.Time is running out for Corbyn to claw back Johnson’s lead ahead of the Dec. 12 general election; a closely watched YouGov poll tonight will provide an indicator of how realistic that is. Dominic Cummings, the premier’s senior adviser, published a blog warning of the “very real possibility” of a hung Parliament as he sought to keep Brexit supporters focused on backing the Tories.Read More: Corbyn Accuses U.K. Tories of Secret NHS Talks With the U.S.The Context: Never Mind Brexit, U.K. Vote Hinges on Future of the NHSELEC for more on the U.K. electionKey Developments:Corbyn’s reveals documents showing six rounds of talks over U.S. trade deal, which he says shows the NHS is “up for sale”YouGov releases MRP poll at 10 p.m. In 2017, it correctly predicted the Conservatives losing their majorityJohnson is campaigning in Cornwall as the Tories pledge to improve mobile phone coverageLiberal Democrats call for gig economy workers on zero-hours contracts to get a 20% higher minimum wageScottish National Party unveils manifesto to “protect Scotland from Boris Johnson”Johnson’s Conservatives have about a 69% chance of a majority in Parliament, according to odds from bookmaker Paddy PowerJohnson’s Top Aide Says Hung Parliament Possible (5:20 p.m.)Boris Johnson’s senior Downing Street adviser appealed to Brexit-supporting voters to help deliver a Conservative majority on Dec. 12 and warned that, despite polls showing big a Tory lead, “things are MUCH tighter than they seem and there is a very real possibility of a hung parliament.”Writing on his blog, Cummings sought to win the backing of Vote Leave supporters who aren’t natural Tories by saying he too had never been part of a political party when he started working in Johnson’s office in July.He urged voters to talk face-to-face to friends and family and tell them a vote for any party except the Tories would lead to a Labour-SNP alliance in government. The referendum that would be offered as a result would be “effectively Remain or Remain,” he wrote.“Without a majority, the nightmare continues,” he said in his intervention, published as voters start casting postal ballots. “ALL other MPs will gang together to stop Brexit and give EU citizens the vote. It’s that simple.”Remainers Urged to Vote Tactically (3 p.m.)Boris Johnson’s Tory Party is on course to win 366 seats on Dec. 12, giving him a majority of 41, according to new data released by anti-Brexit group Best for Britain.The group used MRP data to assess the outlook since Nigel Farage announced his Brexit Party won’t stand in seats won by the Conservatives in 2017.What Is the ‘MRP Poll’ and Can It Predict the U.K. Election?Best for Britain said there are 165 districts where the margin of victory is fewer than 5,000 votes, and urged pro-EU voters in these seats to vote tactically to prevent a pro-Brexit party winning.“Even with the Brexit Party collapse, there are still lots of seats in play for Remainers,” said Naomi Smith, the group’s chief executive. “This is crucial as it means they could be won by pro-EU parties if voters hold their nose and vote for the party with the best shot of beating the Tories.”Separately, favorability ratings for Jo Swinson, leader of the anti-Brexit Liberal Democrats, have “fallen sharply in the past week,” an Ipsos Mori poll showed.Archbishop Raps Tories Over Twitter Deception (2 p.m.)Archbishop of Canterbury Justin Welby criticized Boris Johnson’s Conservative Party for masquerading as a fact-checking organization on Twitter during his debate with Jeremy Corbyn last week.“Where something like that is done, where there is a misleading use of facts, deliberately, that is wrong,” he told the BBC. “We have to have an enormously high value on truth.”He also repeated his support for Chief Rabbi Ephraim Mirvis, who on Tuesday attacked Corbyn over antisemitism in the Labour Party. Welby said he knows Mirvis well, and it was “one of the most painful decisions he’s ever had to take, and I know that’s true. His instincts, like mine and others, are that during an election, you keep schtum, you say nothing,” Welby said. “He felt there was no choice.”Johnson Vows Zero-Tolerance on Prejudice (1 p.m.)Boris Johnson vowed to take a zero-tolerance approach to racism in his Conservative Party and apologized for any offense caused by incidents involving its members.“Whenever we have an incident of antisemitism or Islamophobia or whatever in the Conservative Party, we take a zero-tolerance approach,” the premier told broadcasters. “We have a one bounce and we deal with it approach to this.”He said there will be “an independent inquiry into Islamophobia, antisemitism, every manner of prejudice and discrimination and it will start before Christmas.”With the Labour party facing accusation about antisemitism , the Tories have been charged with Islamophobia. Johnson himself once described Muslim women who wear burkas as looking like “letterboxes” and “bank robbers.”Asked if he apologized for the Islamophobia that has taken place in his party, he replied “look, of course. And for all the hurt and offense that has been caused, of course we do. All that is intolerable.” He wasn’t asked specifically about his own remarks.Johnson Denies NHS Sell-Off Plan (12:20 p.m.)Boris Johnson responded to Jeremy Corbyn’s publication of documents about trade talks with the U.S. (see 10:15 a.m.) with a denial that the NHS will be part of any agreement.“We are absolutely resolved there will be no sale of the NHS, no privatization,” he said in a pooled TV interview while campaigning in Cornwall. “The NHS is not on the table in any way. The NHS is in no way on the table, in no aspect whatever.”The prime minister accused Corbyn of trying to change the focus of the campaign. “It’s continually brought up by the Labour Party as a diversionary tactic from the difficulties they are encountering, particularly over the problem about leadership on antisemitism and then the great vacuity about their policy on Brexit,” Johnson said.Sturgeon: SNP Can ‘Pressure’ Corbyn (12 p.m.)Nicola Sturgeon likened the choice her Scottish National Party may face between Boris Johnson and Jeremy Corbyn in the event of a hung Parliament to picking the “devil or the deep blue sea,” but said despite her misgivings about the Labour leader, his party had far more in common with her social and economic agenda. She ruled out supporting the Conservatives.Following her speech in Glasgow, Sturgeon was asked if she would back Corbyn despite the warning from the U.K.’s chief rabbi this week that the Labour leader is unfit for high office. She criticized Corbyn’s failure to eradicate antisemitism from Labour’s ranks, but pointed out that there are other issues the SNP would also have to consider -- including the path to a second referendum on Scottish independence and stopping Brexit.“We would be very clear with our expectations to any party leader who wanted the support of the SNP to make clear its zero tolerance approach to antisemitism, to Islamophobia, to any form of prejudice or racism,” Sturgeon said. “I think, to those worried about Jeremy Corbyn, it should give a degree of reassurance that SNP MPs, with the right values and approach on these issues, can apply that pressure.”Corbyn’s Key Claims on U.S.-U.K. Negotiations (11 a.m.)Jeremy Corbyn accused the Conservative government of concealing secret negotiations between U.K. and U.S. officials on the future of the NHS in any trade deal. These are the key allegations:U.S. pharmaceutical companies want to force up the price the NHS pays for drugs as part of a U.S.-U.K. Trade deal, he said, noting that Donald Trump regularly complains about the “unreasonably low prices” other countries pay for medicinesThe documents show both sides have finished initial discussions on lengthening patents for medicines in the U.K., Corbyn saidHe said this would mean the U.K. paying U.S. levels for many drugs. He gave the example of AbbVie Inc.’s Humira -- a drug for the treatment of Crohn’s disease and rheumatoid arthritis -- which he said costs the NHS 1,409 pounds ($1,815) a packet, compared to 8,115 pounds ($10,450) in the U.S.He said U.K. officials conceded “NHS access to generic drugs will be a key consideration” in talks, and they are entering a “very advanced stage”Corbyn: Party Has Apologized For Antisemitism (10:40 a.m.)Labour Leader Jeremy Corbyn did not directly say sorry when pressed again on his handling of cases of antisemitism, after he missed several opportunities to apologize in a BBC interview on Tuesday night.“I made it very clear antisemitism is completely wrong in our society,” he said. “Our party did make it clear when I was elected leader, and after, that antisemitism is unacceptable in any form in our party or society and did indeed offer its sympathies and apologies to those that had suffered.”He also said “a very large numbers of other people in the Jewish community do support Labour, do recognize my absolute commitment that every community in our country will be safe under a Labour government.”Corbyn Plays on Trump Fears (10:20 a.m.)Jeremy Corbyn’s speech was heavily infused with the name of the Donald Trump, as he sought to capitalize on Britons’ suspicions of the U.S. president.The document Corbyn referred to (see 10:15 a.m.) includes accounts of trade meetings between U.S. and U.K. officials. He said the account of one meeting showed U.S. officials refusing to include reference to climate change in the trade discussions.“This is not only a plot against our NHS, it’s a plot against our country,” Corbyn said. “What’s at stake in a deal with Trump could not be more important for the country.”“These documents confirm the U.S. Is demanding the NHS is on the table in the trade talks,” Corbyn said. “Big pharma has ripped off and imperiled the health of the American people for years. Now these secret reports show they’re looking to do the same to us if the conservatives are elected on Dec. 12”Corbyn: Secret U.S. Talks Put NHS in Danger (10:15 a.m.)Jeremy Corbyn sought to turn attention to the fate of the National Health Service after his party was hammered over its record on antisemitism.At an event in London, he held up a 451-page unredacted document, which he said showed information Boris Johnson’s government wouldn’t reveal about the status of health care in U.S. trade talks. He said the secret document -- previously only available in a heavily redacted form -- showed that under Johnson, “the NHS is up for sale” in trade talks with the U.S.. The premier’s denials that it isn’t are “in tatters,” he said.The presentation was preceded by a video clip that included U.S. President Donald Trump saying that everything was on the table in trade talks.“This election is now a fight for the survival of our National Health Service,” Corbyn said. “Labour will never ever treat the NHS as a bargaining chip in trade talks with anybody. We will never let Donald Trump get his hands on our NHS.”“Labour will not rest, because unlike the Conservatives we’re not on the side of the billionaires and the bankers. We’re on the side of the nurse, the doctor, the patient and the people, and we will never sell out our national health service.”SNP Manifesto to ‘Protect Scotland’ From Johnson (10 a.m.)The Scottish National Party will unveil its manifesto at an event in Glasgow -- the last major party to do so -- with a pledge to “protect Scotland from Boris Johnson” and a warning there is “much worse to come” if Brexit goes ahead.“A vote for the SNP is a vote to escape Brexit and put Scotland’s future in Scotland’s hands -- not Boris Johnson’s,” SNP leader Nicola Sturgeon will say, according to speech excerpts released by the party. “The future of our country is on the line.​”With the SNP holding a significant poll lead in Scotland, a key question is what the party will do in the event of a hung Parliament on Dec. 12. The SNP’s signature policy is a second referendum on Scottish independence, but more funding for the National Health Service is also a priority.Burgon: Labour ‘Sorry’ for Hurt Over Antisemitism (Earlier)Labour’s justice spokesman Richard Burgon said his party is “sorry for the hurt caused” over its handling of cases of antisemitism, after leader Jeremy Corbyn struggled to explain his strategy and missed several opportunities to apologize in a BBC interview on Tuesday night.“Jeremy has apologized on a number of occasions and said that he’s sorry for the very real hurt felt by people in the Jewish community,” Burgon told the BBC. “On a number of occasions last summer for example, he has made those statements and it’s right that he did.”The latest row over antisemitism in the Labour Party was triggered by the U.K.’s Chief Rabbi Ephraim Mirvis, who suggested this week Corbyn is unfit for high office and said Labour can “no longer claim to be the party of equality and anti-racism.”Jenrick: Tory Islamophobia Probe Will Be ‘Thorough’ (Earlier)Communities Secretary Robert Jenrick insisted the Conservatives will conduct a “thorough” investigation into discrimination and prejudice in the party, after the Muslim Council of Britain criticized Boris Johnson’s Tories over their handling of Islamophobia in their ranks.“I want to see by the end of this year, as the Prime Minister’s promised, a thorough review of prejudice and racism and discrimination within the party,” Jenrick told the BBC. “We want to be a party that has no tolerance whatsoever of racism, prejudice or discrimination of any kind.”Just as Labour has failed to shake off accusations of antisemitism in the party, the Tories are struggling to overcome charges of Islamophobia, exacerbated by Johnson in a 2018 newspaper column in which he said Muslim women who wear burqas look like “letter boxes.”Earlier:Corbyn Can’t Find Antidote to Anti-Semitic ‘Poison’ in LabourU.K. Car-makers Warn Against Flimsy EU Trade Deal After BrexitWhat Is the ‘MRP Poll’ and Can It Predict the U.K. Election?Corbyn Struggles With Anti-Semitism Claims: U.K. Campaign Trail\--With assistance from Robert Hutton and Jessica Shankleman.To contact the reporters on this story: Alex Morales in London at amorales2@bloomberg.net;Greg Ritchie in London at gritchie10@bloomberg.netTo contact the editors responsible for this story: Tim Ross at tross54@bloomberg.net, Stuart Biggs, Thomas PennyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Tory Prime Minister Johnson has held secret talks with U.S. about privatizing National Health Service, Labour rival claims
    MarketWatch

    Tory Prime Minister Johnson has held secret talks with U.S. about privatizing National Health Service, Labour rival claims

    The Conservative prime minister, claims Labour Party leader Jeremy Corbyn, has held secret trade talks with the Trump administration in the U.S.

  • BeiGene Shares Climb Nearly 50% After Amgen Deal
    GuruFocus.com

    BeiGene Shares Climb Nearly 50% After Amgen Deal

    Beijing-based company is first to gain FDA approval for a drug discovered by a Chinese company Continue reading...